Farallon Capital says the results of a recent shareholder vote show it succeeded in refreshing the board at oncology-focused biotech company Exelixis. The $36-billion hedge fund, which owns about 7.8% ...

SAN FRANCISCO--(BUSINESS WIRE)--Farallon Capital Management, L.L.C. (“Farallon”) manages funds that own approximately 7.8% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (“Exelixis” or the ...

Business: Exelixis, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. They have produced ...

SAN FRANCISCO--(BUSINESS WIRE)--Funds managed by Farallon Capital Management L.L.C. (“Farallon”) own approximately 7.2% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (“Exelixis” or the ...

SAN FRANCISCO, SINGAPORE, LONDON, HONG KONG, TOKYO, Nov. 1, 2013 /PRNewswire/ — Noonday Asset Management announced that it will now operate under the name Farallon Capital. The name change unites ...

Add Yahoo as a preferred source to see more of our stories on Google. (Bloomberg) -- Sculptor Capital Management Inc. and Farallon Capital Management LLC are among top distressed debt investors ...

“We’re proud to play a role in bringing high-quality housing to the Fort Greene community and to support a premier sponsorship group in Fetner, Farallon and MCB,” Steve McGuire, head of multifamily ...

Billionaire Democratic presidential candidate Tom Steyer remains an investor in assets tied to the hedge fund he founded. Steyer has made millions through funds tied to his former hedge fund, Farallon ...

It has been an eventful start to the week for investors of genomics-based drug discovery outfit Exelixis (US:EXEL), after the company announced a share buyback worth $550 million pre-market and ...

Farallon Capital Management closed a large investment fund to take advantage of a limited capital environment and the larger “widespread correction” in commercial real estate markets. The firm ...